



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.


다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.




변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.


저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#) 

**Association between fasting serum glucose
levels and incidence of colorectal cancer
: The Korean Cancer Prevention Study-II**


Hyun-Young Shin



Department of Epidemiology
Then Graduate School of Public Health, Yonsei
University

**Association between fasting serum glucose
levels and incidence of colorectal cancer
: The Korean Cancer Prevention Study-II**

Directed by Professor Sun Ha Jee



The Master's Thesis submitted to the Department of
Epidemiology

Then Graduate School of Public Health, Yonsei
University

in partial fulfillment of the requirements for the
degree of Master of Public Health

Hyun-Young Shin

June 2015

This certifies that the dissertation of Hyun-Young Shin is approved.

Thesis Supervisor: Sun Ha Jee

Thesis Committee Member : Hee Cheol Kang

Thesis Committee member : Hee Jin Kimm

Graduate School of Public Health
Yonsei University

July 2015

Acknowledgements

세브란스 병원에서 가정의학과 강사를 시작하면서 새로운 마음으로 보건의대학원에 입학한지 벌써 2-3 여년이 흘렀습니다. 당시에 야심찬 마음으로 새로운 보건분야를 공부하겠다는 의욕을 불사르며 바쁜 와중에도 수업을 꼬박꼬박 참여하기 위해 고군분투했던 기억이 아직도 선명합니다. 그동안에 저는 많이 성장하였습니다. 의과대학, 인턴, 레지던트 그리고 강사시절의 임상경험과 보건의대학원에서의 축적한 보건의료에 대한 이론과 지식이 합쳐져 제 자신을 성숙시켰다고 생각합니다. 특히 제 전공인 역학부분에서의 배움은 소중한 제 성장의 밑거름이 될 것이라고 확신합니다. 고귀한 데이터를 얻어 스스로 통계를 돌려보고 결과물을 교수님들과 논의하던 그 한순간 한순간이 소중합니다. 또한 바쁜 와중에서도 낙오되지 않도록 잘 챙겨주었던 동기들까지 보건의대학원에서의 추억과 인연은 소중한 자산이 되었습니다. 이 자리를 빌어서 지선하 교수님, 김희진 교수님, 박소희 교수님께 감사의 말씀드립니다. 그리고 사랑하는 나의 가족들, 특히 부모님과 물심양면으로 고생 많았던 신랑, 그리고 사랑스런 도담이와 곧 태어날 우리 둘째 아가에게도 이 기쁨을 같이 나누고 싶습니다. 감사합니다.

Table of contents

I. Introduction	1
II. Material and Methods	3
1. Study population	3
2. Questionnaire and anthropometric measurements	4
3. Blood collection and biochemical analyses	4
4. Diagnosis of CRC	4
5. Statistical analysis	5
III. Results	7
IV. Discussion	9
V. Conclusions	13
Acknowledgements/ Funding	14
References	15
Abstract (in Korean)	31

List of figures, List of tables

LIST OF FIGURES

Figure 1. Hazard ratio and 95% confidence interval for colorectal cancer according to fasting serum glucose levels in men.	20
Figure 2. Culmulative colorectal cancer incidence probability according to fasting serum glucose levels.	21
Supplementary Figure 1. Hazard ratio and 95% confidence interval for colorectal cancer according to fasting serum glucose levels in men and women.	22

LIST OF TABLES

Table 1. Basic characteristics of study participants.	23
Table 2. Person year, incident case, and crude incidence rate of colorectal cancer in men and women	24
Table 3. Incidence rate and hazard ratio for developing colorectal cancer in individuals with high or low fasting serum glucose levels ·	25
Table 4. Incidence rate and hazard ratio for developing proximal colon, distal colon, and rectal cancers in individuals with high or low fasting serum glucose levels	26
Supplementary Table 1. Incidence rate and hazard ratio for developing proximal colon, distal colon, and rectal cancers in individuals with high or low fasting serum glucose levels	27

I. Introduction

Colorectal cancer(CRC) is the third and second most common cancer in men and women, respectively, worldwide (Ferlay, et al., 2010). In Korea, it is the third most common cancer overall, and the second most common cancer in men [2]. A Westernized life style and diet is thought to be one of the major reasons for the observed increase in incidence of CRC in Korea and in other developed countries (National Cancer Center, 2014, National Cancer Center, Shin, et al., 2012). Numerous studies have shown that colorectal carcinogenesis is associated with metabolic disorders, such as obesity, metabolic syndrome, and diabetes mellitus; however, the exact mechanisms are currently unclear (Jee, et al., 2008, Ishim, et al., 2013, Giovannucci, et al., 2010).

The incidence of diabetes mellitus has been increasing vastly in most countries, including Korea (Shaw, et al., 2010, Kim, 2011) and it undoubtedly represents one of the most challenging health issues of the 21st century (International Diabetes Federation, 2014). Many studies have reported that diabetes mellitus is related with the increasing incidence of CRC (Giovannucci, et al., 2010, Larsson et al., 2005, Deng et al., 2012, De Bruijn, et al., 2013, Yuhara et al., 2011, Zanders et al., 2014, Inoue et al., 2012). Recently, diabetes mellitus as well as impaired fasting glucose(IFG) as a marker of pre-diabetes, have been spotlighted as a way to minimize the medical and socio-economic burden of diabetes mellitus, by

permitting early detection and intervention. Several studies have reported that pre-diabetes is a possible risk factor of cardiovascular diseases (Barzilay et al., 1999, Kim et al., 2013); however, there is currently no consensus about the association of cancer incidence and IFG. As CRC is broadly known to be a metabolic-related cancer, studying the incidence of CRC and its correlation with fasting serum glucose(FSG) levels could be helpful to design better prevention strategies for controlling the progression and development of CRC.



II. Material and Methods

This study was approved by the institutional review board of the Yonsei University, and all study participants provided written consent, according to the principles of the Declaration of Helsinki.

1. Study population

This is the Korean Metabolic Syndrome Research Initiative study in Seoul, initiated in 2005. The initial study population included 183,336 individuals who visited health promotion centers in university hospitals between 2004 and 2011. Among the total sample population, 278 participants who were diagnosed with colorectal cancer as well as 7132 patients with diabetes mellitus at the time of enrollment were excluded from the study. In addition, 249 subjects with an extremely low body mass index(BMI) <16 kg/m², weight ≤ 30 kg, or height ≤ 130 cm were excluded. Therefore, the final subject group consisted of 175,677 Korean men and women(men, n = 103,452; women, n = 72,225). The mean follow-up period was 4.7 years. A detailed description of the Korean Cancer Prevention Study-II design and methods of selection of participants has been published previously (Jee et al., 2010).

2. Questionnaire and anthropometric measurements

Each participant was interviewed by using a structured questionnaire to collect the following details: education level(<high school vs. ≥high school), smoking history(never smoked, ex-smoker, or current smoker), alcohol drinking(non-drinker vs. consumer of any amount of alcohol on a regular basis), and regular exercise(yes or no). Participant height and weight were measured while the participants were wearing light clothing. BMI was calculated by dividing the weight(kg) by the square height(m²). Systolic and diastolic blood pressures were measured after a rest period of at least 15 min.

3. Blood collection and biochemical analyses

For clinical chemistry assays, serum—separated from peripheral venous blood—was obtained from each participant after a minimum fasting period of 12h, and stored at -70°C until the time of analysis. Levels of FSG, total cholesterol, triglyceride, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were measured by using a COBAS INTEGRA 800 and a Hitachi-7600 analyzer(Hitachi, Tokyo, Japan).

4. Diagnosis of CRC

Data regarding the incidence of CRC was obtained from the records of

the National Cancer Registry and from the hospitals where the participants had been treated. Although Korea has a National Cancer Registry, reports were not complete during the time of follow-up; therefore, hospital admission files were used to identify the first admission events for CRC. An incident of CRC was considered to have occurred on the basis of a positive report either from the National Cancer Registry or upon hospital admission for a cancer diagnosis. According to the International Classification of Diseases, Tenth Revision(ICD-10), CRC was coded as C18-C20 (World Health Organization, 2011).

5. Statistical analysis

Person-years were calculated from the baseline enrollment to 2011, the date of CRC diagnosis, death, or loss of follow-up. Crude incidence rates(per 100,000 person-years) were calculated with the person-years and number of cases of CRC. Hazard ratios(HRs) were calculated by using the Cox proportional hazard model, after adjusting for age, sex, BMI, smoking status, alcohol consumption, and regular exercise. BMI as an indicator of obesity was adjusted in this study for the effect to be minimized. The analyses were performed separately for men and women. Subsequently, the same analyses were used after the FSG levels were divided into high($FSG \geq 100$ mg/dL) or low($FSG < 100$ mg/dL), and into 4 categories on the basis of the cut-offs of 100 mg/dL, 110 mg/dL, and

126mg/dL, in the total population, and in men and women separately. Kaplan-Meier survival analyses were used to evaluate the incidence probability of CRC in the four FSG groups. All statistical tests were two-sided, and statistical significance was determined as $P < 0.05$. SAS statistical software, version 9.2(SAS Institute Inc., Cary, NC) was used for all analyses.



III. Results

The basic characteristics of the participants(103,452 men and 72,225 women) are summarized in Table 1. A total of 320 patients were newly diagnosed with CRC among the 175,677 participants over 816,143 total person-years(mean follow-up, 4.7 years). The crude incidence rates per 100,000 person-years were 39.21 overall, 47.73 for men, and 27.31 for women. The incident rate increased with age in both men and women(Table 2). The HR for developing CRC in subjects with high FSG was statistically significant(HR, 1.40; 95% confidence interval [CI], 1.10 - 1.78), and the association remained significant after adjusting for confounding variables(HR, 1.45; 95% CI, 1.10 - 1.90). When the same analysis was performed according to the sex of the subjects, the HR for developing CRC was relatively high in men(HR, 1.51; 95% CI, 1.11 - 2.05), whereas no association was observed in women (HR, 1.23; 95% CI, 0.67-2.26)(Table 3). When Cox proportional hazards regression models were applied to site-specific CRC, only the HR of rectal cancer was statistically significant in both the total population and men(HR, 1.49; 95% CI, 1.00 - 2.24; HR, 1.59; 95% CI, 1.01 - 2.48, respectively), whereas no significant associations were observed for proximal and distal colon cancers in all groups(Table 4). Increasing trends in the HR of CRC according to the increase of FSG levels were observed(P=0.006 in the total population[Supplementary Fig. 1], P=0.005 in men[Fig. 1], and P=

0.67 in women[data not shown]). When the obese and non-obese groups were sub-analyzed, interestingly, the incidence of distal colon cancer in men was found to be significantly associated with high serum glucose levels in the non-obese group(BMI<25), whereas the incidence of distal colon cancer in women was found to be significantly associated with high serum glucose levels in the obese group(BMI≥25). However, due to the low incidences of distal colorectal cancer in women during a relatively short follow-up period, the confidence interval was observed to be wide. [Supplementary Table 1].

Figure 2 illustrates the incidence trends of CRC during the follow-up period, as determined using the Kaplan-Meier method in the four FSG groups. The cumulative CRC incidence probabilities gradually increased over time, with a sharper increase observed in the high-level FSG groups compared to the low-level FSG groups.

IV. Discussion

In this prospective cohort study of a large Korean population, we found that the incidence of CRC was positively associated with FSG levels. Especially, hyperglycemia including IFG correlated with CRC incidence in men, indicating that pre-diabetes status might be related with colorectal carcinogenesis. This finding was consistent with several previous studies, although the specific classification and study designs differed between the studies. In the Framingham Heart Study-offspring cohort, the incidence of CRC was found to be higher in subjects with IFG. The early exposure of high glucose levels displayed a strong association with CRC, and the HRs proportionally increased with the exposure period of IFG (IFG exposure 5 - 10 y: HR, 1.76; 95% CI, 1.09 - 2.84; 10 - 20y: HR, 2.55; 95% CI, 1.60 - 4.05; and ≥ 20 y: HR, 3.26; 95% CI, 1.73 - 6.14) (Prekh et al., 2013). Another study in Korea, similar to ours, showed the association between IFG and incidence of CRC in men only (glucose, 90 - 109mg/dL: HR, 1.08; 95% CI, 1.01 - 1.15; glucose, 110 - 125mg/dL: HR, 1.14; 95% CI, 1.02 - 1.27), however, unlike in our study, the incidences of site-specific colorectal cancer were not examined (Jee et al., 2005). These two studies were commonly adjusted for age, sex, smoking, and alcohol use, however diet, caloric intake or family history of colorectal cancer were not included.

On the other hand, a prospective cohort study in Austria found that

the association between IFG and the risk of CRC was higher in women (HR, 1.57; 95% CI, 1.08 - 2.28) than in men (HR, 1.37; 95% CI, 0.94 - 2.01) (Rapp et al., 2006). These inconsistent results between men and women might be explained by considering the interaction of sex hormones, inadequate control of confounding factors, and different sample sizes between the studies. Furthermore, a study in a Swedish cohort revealed that the association between hyperglycemia and colon cancer was not significant (Stattin et al., 2007).

There are many hypotheses about the mechanisms behind the potential association between hyperglycemia and CRC. Hyperinsulinemia through insulin-like growth factor signaling (Ish-Shalom et al., 1997, Khandwala et al., 2000, Cohen et al., 2012), chronic inflammation (Yu et al., 2009, Danel et al., 2013), delayed bowel transit time (Will et al., 1998), changes in bile acid (Stadler et al., 1988), and imbalanced microbiota in the bowels (Tlaskalová-Hogenová et al., 2011), have all been suggested. Recently, a study of Kannisto Vetvik et al. demonstrated that involvement of adiponectin-AMP-activated protein kinase α signaling in colorectal carcinogenesis was depending on the glucose levels (Katja et al., 2014). As IFG is an early stage of diabetes mellitus, similar mechanisms are likely responsible for the association between IFG and CRC as well. In addition, the common risk factors of diabetes mellitus and CRC, such as central obesity, high BMI, physical inactivity, and a high-calorie diet, have also been suggested to be the cause of the observed association.

However, the association persisted after controlling for these risk factors in our study, suggesting that this is not the only explanation.

In the present study, the incidence of rectal cancer was associated with elevated glucose levels in men but not in women. There have been several studies about the site-specific relative risks of CRC according to glucose levels, but the results are inconsistent with those of the present study. The Iowa Women's Health study reported that the incidence of proximal colon cancer was associated with diabetes mellitus (Limburg et al., 2005), whereas the study by He et al. and the Nurses' Health study found that the incidence of right and left colon cancer, but not rectal cancer, were significantly associated with diabetes mellitus (He et al., 2010, Hu et al., 1999). Moreover, a prospective study in Sweden demonstrated a slightly higher risk of cecum/ascending colon cancer compared to other sites of CRC in patients with diabetes mellitus (Weiderpass et al., 1997). Rectal cancer is known to be the most common subsite of colorectal cancer in Asian male (Shin et al., 2012), whereas proximal colon cancer is known to be the most common site of colorectal cancer for Asian women, Whites and Blacks living in U.S. (Murphy et al., 2011, Wu et al., 2004). This might be the one of the contributing factors of the association. However, the mechanisms behind the site-specific incidence of CRC, and its association with hyperglycemia, have not yet been fully explained.

When the glucose levels were sub-classified into 4 categories in our study, the HR of each group displayed an increase in trend in the incidence of CRC; however, the HRs were not statistically significant in the group with fasting glucose levels of 110 to 126mg/dL. This might be owing to the sample size of patients with CRC and the study duration not being sufficient, leading to poor statistical power.

There are several limitations to our study. First, the participants in the cohort were followed-up for a relatively short period, and therefore it may not have been enough time to fully detect the cancer incidence. Second, no information about insulin levels, cancer stages, and comorbidities were available for this study, and may have been confounding factors, making the association between CRC and FSG levels more complicated to establish. Third, this cohort consisted of people who visited health screening centers at university hospitals, and, therefore, selection bias existed. Moreover, variability in the laboratory methods used at each center might have influenced the results. Lastly, the cases of colorectal cancer occurred during the first year, included in the analysis, may have little effect from glucose level during carcinogenesis. However, when those cases were excluded in the analysis, the association between elevated glucose level and rectal cancer incidence was observed to be attenuated. Despite the limitations, a major strength of this study is that it represents the largest cohort study performed to date, with 19 multi-centers in Korea tracking the nationwide incidence of cancer.

V. Conclusions

Our findings suggest that pre-diabetes and diabetes statuses are related with CRC development and progression in men. Based on these results, early detection and intervention aimed at controlling fasting serum glucose level may represent a novel way of preventing colorectal carcinogenesis. Further experimental studies and larger, longer prospective epidemiologic studies are needed to fully understand the biological and molecular mechanisms of hyperglycemia and its association with carcinogenesis and the incidence of site-specific CRC.



Acknowledgements/ Funding

This work was supported by an extramural grant from the Seoul R&BD program, Republic of Korea(10526); a grant from the National R&D Program for Cancer Control; Ministry for Health, Welfare and Family Affairs, Republic of Korea(0920330); the National Research Foundation of Korea(NRF) grant, funded by the Korea government(MEST) (No. 2011-0029348); and a grant from the National R&D Program for Cancer Control; Ministry for Health, Welfare and Family Affairs, Republic of Korea(1220180).



References

- American Cancer Society. Cancer facts & figures 2013. Accessed at <http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013> on 5 March 2014.
- Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furberg CD, Dobs A, Polak JF, Savage PJ. Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. *Lancet* 1999;354:622-5.
- Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and IGF connection. *Endocr Relat Cancer* 2012;19:27-45.
- Daniel S. Straus. TNF α and IL-17 cooperatively stimulate glucose metabolism and growth factor production in human colorectal cancer cells. *Mol Cancer*. 2013;12:78.
- De Bruijn KM, Arends LR, Hansen BE, S. Leeflang, R. Ruiter, C. H. J. van Eijck . Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. *Br J Surg* 2013;100:1421-9.
- Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. *Dig Dis Sci* 2012;57:1576-85.

Ferlay J, Shin HR, Bray F, Forman D, Mathers, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2010;127:2893 - 917.

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. *Diabetes Care* 2010;33:1674-85.

He J, Stram DO, Kolonel LN, Le Marchand L, Haiman CA. The association of diabetes with colorectal cancer risk: the Multiethnic Cohort. *Br J Cancer* 2010;103:120-6.

Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E. Prospective Study of Adult Onset Diabetes Mellitus (Type 2) and Risk of Colorectal Cancer in Women. *J Natl Cancer Inst* 1999;91:542-7.

Inoue M, Tsugane S. Insulin resistance and cancer: epidemiological evidence. *Endocr Relat Cancer* 2012;19:F1-F8.

International Diabetes Federation. *IDF Diabetes Atlas*. 6th edn. Accessed at:

<http://www.idf.org/diabetesatlas/download-book> accessed on 5 March 2014.

- Ishim K, Mutoh M, Totsuka Y, Nakagama H. Metabolic syndrome: A novel high-risk state for colorectal cancer. *Cancer Let* 2013;334:56-61.
- Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM, Naor D, De Meyts P. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. *Diabetologia* 1997;40(Suppl 2):S25 - S31.
- Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting Serum Glucose Level and Cancer Risk in Korean Men and Women. *JAMA*2005;293:194-202.
- Jee SH, Sull JW, Lee JE, Shin C, Park J, Kimm H, Cho EY, Shin ES, Yun JE, Park JW, Kim SY, Lee SJ, Jee EJ, Baik I, Kao L, Yoon SK, Jang Y, Beaty TH. Adiponectin concentrations: a genome-wide association study. *Am J Hum Genet* 2010;87:545-52.
- Jee SH, Yun JE, Park EJ, Cho ER, Park IS, Sull JW, Ohrr H, Samet JM.. Body mass index and cancer risk in Korean men and women. *Int J Cancer* 2008;123:1892-6.
- Katja Kannisto Vetvik, Tonje Sonerud, Mona Lindeberg, Lüders T, Størkson RH, Jonsdottir K, Frengen E, Pietiläinen KH, Bukholm I. Globular adiponectin and its downstream target genes are up-regulated locally in human colorectal tumors: ex vivo and in

vitro studies. *Metabolism Clinical and Experimental* 2014;63:672-81.

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. *Endocr Rev* 2000;21:215-44.

Kim DJ. The Epidemiology of Diabetes in Korea. *Diabetes Metab J* 2011;35:303-8.

Kim HK, Kim CH, Kim EH, Bae SJ, Choe J, Park JY, Park SW, Yun YD, Baek SJ, Mok Y, Jee SH. Impaired Fasting Glucose and Risk of Cardiovascular Disease in Korean Men and Women : The Korean Heart Study. *Diabetes Care* 2013;36:328-35.

Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. *J Natl Cancer Inst* 2005;97:1679-87.

Limburg PJ, Anderson KE, Johnson TW, bs DR Jr, Lazovich D, Hong CP, Nicodemus KK, Folsom AR. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study. *Cancer Epidemiol Biomarkers Prev* 2005;14:133-7.

Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. *Int J Cancer*. 2011; 128:1668-75.

- National Cancer Center, Ministry for Health and Welfare, Cancer fact and figures 2013 in the republic of Korea. 1st ed. 2013. Accessed at <http://ncc.re.kr/english/cyber/publi01.jsp> on 5 March 2014.
- Parekh N, Lin Y, Vadiveloo M, Hayes RB, Lu-Yao GL. Metabolic Dysregulation of the Insulin - Glucose Axis and Risk of Obesity-Related Cancers in the Framingham Heart Study-Offspring Cohort (1971 - 2008) *Cancer Epidemiol Biomarkers Prev* 2013;22:1825-36.
- Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, Oberaigner W, Weiland SK. Fasting serum glucose and cancer risk in a cohort of more than 140,000 adults in Austria. *Diabetologia* 2006;49:945-52.
- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. *Diabetes Res Clin Pract* 2010;87:4-14.
- Shin A, Kim KZ, Jung KW, Park S, Won YJ, Kim J, Kim DY, Oh JH. Increasing Trend of Colorectal Cancer Incidence in Korea, 1999-2009. *Cancer Res Treat* 2012;44:219-26.
- Stadler J, Yeung KS, Furrer R, Marcon N, Himal HS, Bruce WR. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer. *Cancer Lett* 1988;38:315-20.

Stattin P, Björ O, Ferrari P, Lukanova A, Lenner P, Lindahl B, Hallmans G, Kaaks R. Prospective Study of Hyperglycemia and Cancer Risk. *Diabetes Care* 2007;30:561-7.

Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z, Klimešová K, Příbylová J, Bártová J, Sanchez D, Fundová P, Borovská D, Srůtková D, Zídek Z, Schwarzer M, Drastich P, Funda DP. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. *Cell Mol Immunol* 2011;8:110-20.

Weiderpass E, Gridley G, Nyrén O, Ekblom A, Persson I, Adami HO. Diabetes Mellitus and Risk of Large Bowel Cancer. *J Natl Cancer Inst* 1997;89:660-1.

Will JC, Galuska DA, Vinicor, F, Calle EE. Colorectal Cancer: Another Complication of Diabetes Mellitus? *Am J Epidemiol* 1998;147:816-25.

World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision Volume 2 Instruction manual 2010 Edition. Geneva, Switzerland: WHO press; 2011.


Wu X, Chen VW, Martin J, Roffers S, Groves FD, Correa CN, Hamilton-Byrd E, Jemal A; Comparative Analysis of Incidence Rates Subcommittee, Data Evaluation and Publication Committee, North American Association of Central Cancer Registries. Subsite-specific colorectal cancer incidence rates and stage distributions among Asians and Pacific Islanders in the United States, 1995 to 1999. *Cancer Epidemiol Biomarkers Prev.* 2004; 13:1215-22.

Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. *Nat Rev Cancer* 2009;9:798-809.

Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? *Am J Gastroenterol* 2011;106:1911-21.

Zanders MM, Vissers PA, Haak HR, van de Poll-Franse LV. Colorectal cancer, diabetes and survival: Epidemiological insights. *Diabetes Metabol* 2014;40(2):120-7.

Figure 1. Hazard ratio and 95% confidence interval for colorectal cancer according to fasting serum glucose levels in men.




Abbreviations: HR, Hazard Ratio; FSG, fasting serum glucose

*HR from Cox proportional hazards regression analysis adjusted for age, sex, body mass index, smoking, alcohol drinking, and regular exercise. (P trend =0.03)

† P value < 0.05


Figure 2. Culmulative colorectal cancer incidence probability according to fasting serum glucose levels.



Abbreviations: CRC, colorectal cancer; FSG, fasting serum glucose

*Cumulative CRC Incidence Probability, using Kaplan-Meier survival analysis.

Supplementary Figure 1. Hazard ratio and 95% confidence interval for colorectal cancer according to fasting serum glucose levels in men and women.



Abbreviations: HR, Hazard Ratio; FSG, fasting serum glucose

HR* from Cox proportional hazards regression analysis adjusted for age, sex, body mass index, smoking, alcohol drinking, and regular exercise. (P trend =0.04)

† P value < 0.05

Table 1. Basic characteristics of study participants.

Total (n=175,677)	Men (n=103,452)	Women (n=72,225)
Variables	Mean ± SD	Mean ± SD
Age (years)	42.0 ± 9.8	41.5 ± 11.2
BMI (kg/m²)	24.4 ± 2.9	22.3 ± 3.1
Systolic BP (mmHg)	121.4 ± 13.5	112.9 ± 15.1
Diastolic BP (mmHg)	76.6 ± 10.0	70.6 ± 10.1
FSG (mg/dL)	94.0 ± 16.7	87.9 ± 13.3
Total cholesterol (mmol/L)	192.7 ± 33.4	184.6 ± 33.3
Triglyceride (mmol/L)	158.0 ± 100.7	100.5 ± 60.4
HDL-cholesterol (mmol/L)	49.1 ± 9.7	57.7 ± 11.4
LDL-cholesterol (mmol/L)	115.8 ± 62.2	108.0 ± 30.8

Abbreviations: BMI, body mass index, BP, blood pressure; FSG, fasting serum glucose; HDL, high-density lipoprotein; LDL, low-density lipoprotein

Table 2. Person year, incident case, and crude incidence rate of colorectal cancer in men and women

	Men (n=103,452)			Women (n=72,225)		
	Person-year	CRC	IR ^a	Person-year	CRC	IR ^a
Overall	816142.7	320	39.21			
Sex	475625.3	227	47.73	340497.9	93	27.31
Duration of f/u (years)						
<1	87.8	23	26195.9	77.2	16	20725.4
1 - 2	841.4	27	3208.9	701.0	9	1283.9
2 - 3	1804.0	20	1108.6	1179.9	12	1017.0
3 - 4	127695.0	45	35.2	90426.5	19	21.0
4 ≤	345209.6	112	32.4	248120.3	37	14.9
Location of CRC						
Proximal	95.7	35	36572.6	61.9	24	38772.2
Distal	162.8	66	40540.5	45.8	25	54585.2
Rectal	287.1	113	39359.1	104.4	40	38314.2

Abbreviations: CRC, colorectal cancer; IR, incidence rate; PY, Person-year

^a Incidence rate per 100,000 person-year

Table 3. Incidence rate and hazard ratio for developing colorectal cancer in individuals with high or low fasting serum glucose levels

	Person-year	CRC	IR ^a	HR ^b	95% CI	HR ^c	95% CI	HR ^d	95% CI
Fasting serum glucose^e (Total)									
Low	677675.6	221	32.61	1.00		1.00		1.00	
High	138467.0	99	71.50	1.40	1.10-1.78	1.45	1.11-1.90	1.45	1.10-1.90
Fasting serum glucose^e (Men)									
Low	375362.6	145	38.63	1.00		1.00		1.00	
High	100275.2	82	81.77	1.54	1.17-2.02	1.51	1.12-2.05	1.51	1.11-2.05
Fasting serum glucose^e (Women)									
Low	302313.0	76	25.14	1.00		1.00		1.00	
High	38191.9	17	44.51	0.99	0.57-1.70	1.25	0.68-2.28	1.23	0.67-2.26

Abbreviations: CRC, colorectal cancer; IR, incidence rate, HR, hazard ratio; CI, confidence interval

^a Incidence rate per 100,000 person-year

^b Cox proportional hazards regression analysis adjusted for age and sex.

^c Cox proportional hazards regression analysis adjusted for age, sex, and body mass index.

^d Cox proportional hazards regression analysis adjusted for age, sex, body mass index, smoking, alcohol drinking, and regular exercise.

^e Low <100 mg/dL, high ≥100 mg/dL

Table 4. Incidence rate and hazard ratio for developing proximal colon, distal colon, and rectal cancers in individuals with high or low fasting serum glucose levels

	Proximal Colon Cancer		Distal Colon Cancer		Rectal Cancer	
	HR ^a	95% CI	HR ^a	95% CI	HR ^a	95% CI
Fasting serum glucose^b (Total)						
Low	1.00		1.00		1.00	
High	1.42	0.77-2.62	1.60	0.99-2.61	1.49	1.00-2.24
Fasting serum glucose^b (Men)						
Low	1.00		1.00		1.00	
High	1.69	0.81-3.53	1.53	0.88-2.64	1.59	1.01-2.48
Fasting serum glucose^b (Women)						
Low	1.00		1.00		1.00	
High	1.11	1.06-1.15	1.94	0.66-5.66	1.12	0.41-3.06

Abbreviations: HR, hazard ratio; CI, confidence interval

a Cox proportional hazards regression analysis adjusted for age, sex, body mass index, smoking, alcohol drinking, and regular exercise.

^b Low <100 mg/dL, high ≥100 mg/dL

Supplementary Table 1. Incidence rate and hazard ratio for developing proximal colon, distal colon, and rectal cancers in individuals with high or low fasting serum glucose levels

	Proximal Colon Cancer		Distal Colon Cancer		Rectal Cancer	
	HR ^a	95% CI	HR ^a	95% CI	HR ^a	95% CI
BMI<25	Fasting blood sugar^b (Total)					
Low	1.00		1.00		1.00	
High	1.74	0.79-3.84	1.69	0.95-3.02	2.04	1.21-3.46
	Fasting blood sugar^b (Men)					
Low	1.00		1.00		1.00	
High	2.10	0.81-5.42	1.98	1.06-3.71	2.31	1.30-4.10
	Fasting blood sugar^b (Women)					
Low	1.00		1.00		1.00	
High	1.03	0.22-4.84	0.56	0.07-4.41	1.08	0.24-4.83
BMI≥25	Fasting blood sugar^b (Total)					
Low	1.00		1.00		1.00	
High	1.18	0.46-2.99	1.54	0.64-3.70	1.00	0.54-1.84
	Fasting blood sugar^b (Men)					
Low	1.00		1.00		1.00	
High	1.31	0.42-4.08	0.89	0.31-2.59	1.00	0.50-2.00
	Fasting blood sugar^b (Women)					
Low	1.00		1.00		1.00	
High	0.93	0.18-4.86	11.05	1.21-101.15	0.98	0.26-3.70

Abbreviations: BMI, body mass index; HR, hazard ratio; CI, confidence interval

^a Cox proportional hazards regression analysis adjusted for age, sex, body mass index, smoking, alcohol drinking, and regular exercise.

^b Low <100 mg/dL, high ≥100 mg/dL

Abstract

Association between fasting serum glucose levels and incidence of colorectal cancer : The Korean Cancer Prevention Study-II

Hyun-Young Shin

Department of Epidemiology

Then Graduate School of Public Health, Yonsei University

Directed by Professor Sun Ha Jee

The incidence of colorectal cancer(CRC) is steadily increasing worldwide. Numerous studies have demonstrated that diabetes mellitus is related to an increased risk of CRC; however, the association between impaired fasting glucose and CRC is unclear. Therefore, we evaluated the correlation between the incidence of fasting serum glucose(FSG) levels and CRC, which can be used to develop novel methods for preventing CRC.

A total of 183,336 individuals from the Korean Metabolic Syndrome Research Initiative study were enrolled between 2004 and 2011. The incidence of CRC was assessed during a mean follow-up of 4.7 years. Hazard ratios(HR) for CRC according to FSG levels were calculated with

the Cox proportional hazard model adjusted for age, sex, body mass index, smoking status, alcohol consumption, and regular exercise.

The risk of developing CRC in subjects with high FSG was significant(HR, 1.45; 95% confidence interval [CI], 1.10 - 1.90) in total population, and the risk was higher in men(HR, 1.51; 95% CI, 1.11 - 2.05). The HR of rectal cancer was significantly higher in men in the high FSG group and the HR of proximal cancer was significantly higher in women in the high FSG group.

The incidence of CRC positively correlated with FSG levels in men. Therefore, early detection and intervention for controlling elevated glucose levels may be indicated as a way to prevent carcinogenesis. Further studies are needed to elucidate the biological and molecular mechanisms of hyperglycemia and its relationship with carcinogenesis and the site-specific incidence of CRC.

Key Words: colorectal cancer, fasting serum glucose, hyperglycemia, impaired fasting glucose, incidence, rectal cancer

**Association between fasting serum glucose levels and
incidence of colorectal cancer
: The Korean Cancer Prevention Study-II**

Hyun-Young Shin

Department of Epidemiology

Then Graduate School of Public Health, Yonsei University

(Directed by Professor Sun Ha Jee)



I. INTRODUCTION

II. MATERIALS AND METHODS

III. RESULTS

IV. DISCUSSION

V. CONCLUSION

REFERENCES

Abstract (in Korean)

한국인에서의 공복혈당과 대장암 발생의 관련성 연구

: The Korean Cancer Prevention Study-II

<지도교수 지선하>

연세대학교 보건대학원 역학과

신현영


연구배경 : 전세계적으로 대장암 발병이 증가하고 있는 가운데, 수많은 연구를 통해 당뇨와 대장암의 연관성에 대해 보고되어 왔다. 하지만 공복혈당과 대장암과의 관련성은 아직 명확하지 않은 상태이다. 본연구의 목적은 공복혈당과 대장암의 관련성을 확인하여, 대장암 예방에 기여할 수 있을 위험인자를 확인하고자 한다.

방법 : 2004년부터 2011까지의 Korean Metabolic Syndrome Research Initiative study에서 183,336명의 참가자를 모집하고, 평균 4.7년동안의 추적 관찰을 통하여 대장암의 발병사례를 수집한다. 나이, 성별, 비만도, 흡연여부, 음주여부 및 운동상태를 보정한 Cox proportional hazard model 을 통하여 대장암 발병의 Hazard ratios를 구한다.

결과 : 한국남성에서 대장암 발병과 공복혈당과의 양의 상관관계를 확인

하였다. 특히, 대장암 발병 위치에 따른 분석에서, 남성은 직장암에서, 여성은 근위부 대장암에서 높은 공복혈당과 관련성이 있음을 확인하였다. 그러므로 공복혈당을 조기에 발견하고 이를 낮추기 위한 노력이 대장암 형성과정을 예방할 수 있을 것으로 기대한다. 앞으로 높은 공복혈당과 암형성과정의 분자생물학적인 메커니즘과 대장암 발생위치와의 관련성을 밝혀내기 위한 추가적인 연구가 필요할 것으로 사료된다.

핵심되는 말 : 대장암, 공복혈당, 고혈당, 내당능장애, 발병, 직장암



PUBLICATION LIST----- pt

